

Anders Sjølander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2118072/publications.pdf>

Version: 2024-02-01

44
papers

1,388
citations

430874

18
h-index

345221

36
g-index

44
all docs

44
docs citations

44
times ranked

2291
citing authors

#	ARTICLE	IF	CITATIONS
1	Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study. <i>American Journal of Hematology</i> , 2022, 97, 421-430.	4.1	7
2	Efficacy and safety of warfarin in patients with non-valvular atrial fibrillation and CKD G3–G5D. CKJ: <i>Clinical Kidney Journal</i> , 2022, 15, 1169-1178.	2.9	6
3	Time to initiation of lipid-lowering drugs for subclinical atherosclerosis: sub-study of VIPVIZA randomized controlled trial, with single-arm cross-over. <i>European Heart Journal Open</i> , 2022, 2, .	2.3	2
4	MO758: Warfarin Treatment Quality and Outcomes in Patients with Non-Valvular Atrial Fibrillation and Chronic Kidney Disease Including Patients on Dialysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
5	Incidence and risk factors of venous thromboembolism in men and women. <i>Thrombosis Research</i> , 2022, 214, 82-86.	1.7	9
6	Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI. <i>Leukemia</i> , 2021, 35, 2416-2418.	7.2	13
7	Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population-based Swedish chronic myeloid leukaemia registry. <i>British Journal of Haematology</i> , 2021, 193, 915-921.	2.5	9
8	Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome—A retrospective observational study. <i>PLoS ONE</i> , 2021, 16, e0255009.	2.5	4
9	Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population. <i>Circulation</i> , 2021, 144, 916-929.	1.6	164
10	Increased Risk of Chronic Myeloid Leukemia Following Gastric Conditions Indicating Helicobacter pylori Infection: A Case–Control Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 151-156.	2.5	3
11	Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 315-323.	2.1	4
12	Predictors for INR-control in a well-managed warfarin treatment setting. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 227-232.	2.1	10
13	Triple therapy after PCI — Warfarin treatment quality and bleeding risk. <i>PLoS ONE</i> , 2018, 13, e0209187.	2.5	3
14	Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. <i>Thrombosis Research</i> , 2018, 167, 113-118.	1.7	29
15	Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis. <i>Heart</i> , 2017, 103, 198-203.	2.9	33
16	Safety and Efficacy of Bridging With Low-Molecular-Weight Heparin During Temporary Interruptions of Warfarin: A Register-Based Cohort Study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 961-966.	1.7	9
17	The impact of socio-economic factors on treatment choice and mortality in chronic myeloid leukaemia. <i>European Journal of Haematology</i> , 2017, 98, 398-406.	2.2	14
18	Ischemic stroke rates decline in patients with atrial fibrillation as anticoagulants uptake improves: A Swedish cohort study. <i>Thrombosis Research</i> , 2017, 158, 44-48.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Venous thromboembolism and cancer risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 68-73.	2.1	20
20	Advanced phase chronic myeloid leukaemia (CML) in the tyrosine kinase inhibitor era – a report from the Swedish CML register. <i>European Journal of Haematology</i> , 2017, 98, 57-66.	2.2	13
21	Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 146.	6.1	54
22	Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. <i>PLoS ONE</i> , 2017, 12, e0181000.	2.5	28
23	Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. <i>European Journal of Haematology</i> , 2016, 97, 387-392.	2.2	31
24	Warfarin persistence among atrial fibrillation patients – why is treatment ended?. <i>Cardiovascular Therapeutics</i> , 2016, 34, 468-474.	2.5	7
25	Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. <i>Annals of Internal Medicine</i> , 2016, 165, 161.	3.9	86
26	Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study. <i>Thrombosis Research</i> , 2016, 140, 94-99.	1.7	20
27	Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 172.	6.1	119
28	Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis: A nationwide population-based study. <i>American Heart Journal</i> , 2016, 181, 1-9.	2.7	24
29	Bleeding complications in venous thrombosis patients on well-managed warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 351-358.	2.1	14
30	No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries. <i>Blood</i> , 2016, 128, 1896-1896.	1.4	0
31	Warfarin treatment complications do not correlate to cTTR when above 70%. <i>Thrombosis Research</i> , 2015, 136, 1185-1189.	1.7	8
32	Safety and efficacy of well managed warfarin. <i>Thrombosis and Haemostasis</i> , 2015, 113, 1370-1377.	3.4	127
33	INR variability and outcomes in patients with mechanical heart valve prosthesis. <i>Thrombosis Research</i> , 2015, 136, 1211-1215.	1.7	13
34	Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. <i>Thrombosis Research</i> , 2015, 136, 216-220.	1.7	37
35	Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era. <i>British Journal of Haematology</i> , 2015, 169, 683-688.	2.5	49
36	Glomerular filtration rate and association to stroke, major bleeding, and death in patients with mechanical heart valve prosthesis. <i>American Heart Journal</i> , 2015, 170, 559-565.	2.7	8

#	ARTICLE	IF	CITATIONS
37	Warfarin persistence among stroke patients with atrial fibrillation. <i>Thrombosis Research</i> , 2015, 136, 744-748.	1.7	10
38	Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1586-1586.	1.4	1
39	Mature, Adaptive-like CD56DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission. <i>Blood</i> , 2015, 126, 343-343.	1.4	3
40	Thromboembolism, major bleeding and mortality in patients with mechanical heart valves- a population-based cohort study. <i>Thrombosis Research</i> , 2014, 134, 354-359.	1.7	26
41	Mechanical heart valve prosthesis and warfarin – Treatment quality and prognosis. <i>Thrombosis Research</i> , 2014, 133, 795-798.	1.7	25
42	Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. <i>Blood</i> , 2013, 122, 1284-1292.	1.4	110
43	Disease Relapse After TKI Discontinuation In CML Is Related Both To Low Number and Impaired Function Of NK-Cells:Data From Euro-SKI. <i>Blood</i> , 2013, 122, 379-379.	1.4	12
44	Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. <i>European Heart Journal</i> , 2011, 32, 2282-2289.	2.2	218